News & Events
Keep up to date with Isogenica’s latest news on collaborations, Press Releases, Events and VHH antibody resources.
Isogenica’s
Latest News

University of Leicester strikes partnership with biotech experts Isogenica to develop personalised cancer treatments
UK-based antibody engineering experts Isogenica are proud to announce a new collaboration with the Frederick National Laboratory for Cancer Research in Maryland USA.
Isogenica turns 25: Our journey
We’ve come a long way over the past quarter century, from our early years as a therapeutic peptide discovery company to specialising in VHH antibodies. Here’s the story…
Isogenica and Frederick National Laboratory for Cancer Research add two more projects to their contractual relationship
UK-based antibody engineering experts Isogenica are proud to announce a new collaboration with the Frederick National Laboratory for Cancer Research in Maryland USA.
Events
Isogenica are always looking to learn and connect at upcoming events and conferences.

Events
Resources
Due to their unique characteristics, VHH are promising candidates for a range of application areas including intracellular targeting and even across the Blood Brain Barrier (BBB). Discover all the benefits in using VHH in different applications.
The golden age of bi-specific antibodies is here
Bi-specific antibodies (BsAbs) – antibodies that can recognise two different epitopes on either the same or different antigens – have been around for a long time. However, in the past few years we’ve seen a renaissance in the design and application of these molecules.
On the Origin of VHHs: Student serendipity and coincidental camels
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
Webinars
Webinars are a great source for the latest activities at Isogenica. Hear all about the newest applications of VHH.
Nature Webinar
Register for Isogenica's upcoming webinar Join Isogenica for the upcoming webinar with Nature on 'VHH as building blocks for immune and tumour cell-targeting', presented by Isogenica's CSO Bill...

Isogenica’s
Newsletters
Catch up with Isogenica’s news and activies through the latest Newsletters.
🩸 This month we’re talking blood cancer and bi-specifics
Not many Biotechs get to turn 25, but this month at Isogenica we are celebrating our quarter century! This edition we look back through our 25 years of new technologies, acknowledging our wonderful partnerships….
🎂 Join us in celebrating our 25th birthday
Not many Biotechs get to turn 25, but this month at Isogenica we are celebrating our quarter century! This edition we look back through our 25 years of new technologies, acknowledging our wonderful partnerships….
📣 Synthetic libraries are our forte and here’s why…
This edition we’re talking synthetic libraries: read on to see how we can save up to 8 months on immunisation alone compared with traditional approaches. Since November we’ve seen Dave attend Genesis in London, Ben go to PEGS, Barcelona, and Marion off to CAR-T, London….
Small is beautiful – VHHs for next generation cell therapies
We’re experts on VHH antibodies. Read on to discover the advantages of using VHHs in CAR targeting, our recently launched ISOXTEND® technology, and how our VHHs are being tested in a potential new therapy for heart failure…
Creating the next generation of immunotherapies
Immunotherapy has transformed the cancer treatment landscape in recent years, harnessing the power of the immune system to target cancer cells. However, checkpoint inhibitor drugs don’t work for all patients, so the hunt is on for more targeted and personalised therapies that directly engage immune cells with cancer cells.
Isogenica Launches A New Library Boosting Outputs For Vhh Antibody Discovery
Introducing VHHantage™ allowing maximised diversity humanised VHH binders with significantly reduced liabilties, allowing the efficient discovery developable antibodies.
Isogenica Vhh Bi And Multispecific Plugandplay Platform
Isogenica have developed fully synthetic, in vitro plugandplay cassettebased approach to efficiently generate combinations of bi and trispecific VHH, exemplified in in vitro studies.
Upcoming Nature Webinar: VHH as building blocks for immune and tumour cell-targeting
Tune in to hear Isogenica’s CSO Dr Bill Eldridge describe applications of naturally monovalent antibody domain structure combined to generate the next generation of multi-specific biologics.
Isogenica Is Attending Bio Digital 2021
Meet David Mead, Director of Business Development and Associate Director of Marketing, Dr Mandeep Sehmi at the BIO International Convention Digital 2021 June 10-11 & 14-18, to learn the latest developments of VHH single domain antibodies to tumour targets.
Using Llama-vhh To Optimize T-cell Mediated Immunotherapies
Listen to Senior Director of Antibody Discovery Dr Ed McGowan and his thorough review of the applications of VHH single domain antibodies in CAR-T and T cell engagers.